Tianshu Liu

7PUBLICATIONS
31CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsCancer geneticsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jun 30, 2025
A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors.

Geoffrey Ku, Lin Shen, Farshid Dayyani

|Aug 23, 2024
Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study.

Xiaojing Xu, Luoyan Ai, Keshu Hu

|Jul 13, 2024
IL-4/IL-4R axis signaling drives resistance to immunotherapy by inducing the upregulation of Fcγ receptor IIB in M2 macrophages.

Jiayu Zhang, Yu Dong, Shan Yu

|Mar 30, 2024
ScRNA-seq of gastric cancer tissues reveals differences in the immune microenvironment of primary tumors and metastases.

Yu Dong, Keshu Hu, Jiayu Zhang

|Sep 21, 2022
Heparanase modulates the prognosis and development of BRAF V600E-mutant colorectal cancer by regulating AKT/p27Kip1/Cyclin E2 pathway.

Mengling Liu, Xiaojing Xu, Ke Peng

|Jun 25, 2022
Phase I study of adjuvant chemotherapy with nab-paclitaxel and S-1 for stage III Lauren's diffuse-type gastric cancer after D2 resection (NORDICA study).

Yuehong Cui, Yiyi Yu, Shan Yu

Pageof 2

Frequent Collaborators

2 joint publications

Li Liang

1 joint publications

Yiyi Yu

1 joint publications

Keshu Hu

1 joint publications

Pengfei Zhang